Seema A. Khan

11.7k total citations · 2 hit papers
229 papers, 7.3k citations indexed

About

Seema A. Khan is a scholar working on Cancer Research, Oncology and Genetics. According to data from OpenAlex, Seema A. Khan has authored 229 papers receiving a total of 7.3k indexed citations (citations by other indexed papers that have themselves been cited), including 113 papers in Cancer Research, 100 papers in Oncology and 60 papers in Genetics. Recurrent topics in Seema A. Khan's work include Breast Cancer Treatment Studies (96 papers), Estrogen and related hormone effects (42 papers) and Breast Lesions and Carcinomas (40 papers). Seema A. Khan is often cited by papers focused on Breast Cancer Treatment Studies (96 papers), Estrogen and related hormone effects (42 papers) and Breast Lesions and Carcinomas (40 papers). Seema A. Khan collaborates with scholars based in United States, Australia and Switzerland. Seema A. Khan's co-authors include Monica Morrow, Gary M. Freedman, Armando E. Giuliano, Suzanne Klimberg, Stuart J. Schnitt, Janet K. Horton, Nehmat Houssami, Jay R. Harris, Meena S. Moran and Mariana Chávez‐MacGregor and has published in prestigious journals such as The Lancet, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Seema A. Khan

219 papers receiving 7.1k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline

2021 592 citations Larissa A. Korde, Mark R. Somerfield et al. Journal of Clinical Oncology profile →
Society of Surgical Oncology–American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer

2014 451 citations Meena S. Moran, Stuart J. Schnitt et al. Annals of Surgical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Seema A. Khan United States	41	3.2k	2.5k	1.7k	1.6k	1.4k	229	7.3k
Seok Jin Nam South Korea	47	3.4k 1.0×	3.5k 1.4×	1.9k 1.1×	1.4k 0.9×	1.9k 1.4×	427	8.9k
Craig D. Shriver United States	44	3.2k 1.0×	3.3k 1.3×	1.9k 1.1×	2.2k 1.4×	2.2k 1.5×	316	8.7k
Byeong‐Woo Park South Korea	42	2.4k 0.7×	2.4k 0.9×	1.5k 0.9×	801 0.5×	1.0k 0.7×	210	5.3k
N. J. O’Higgins Ireland	50	2.9k 0.9×	2.8k 1.1×	1.1k 0.7×	1.0k 0.7×	2.2k 1.5×	185	6.8k
Alastair M. Thompson United States	55	3.9k 1.2×	4.6k 1.8×	1.6k 0.9×	1.6k 1.0×	2.7k 1.9×	283	10.0k
Robert E. Mansel United Kingdom	53	4.4k 1.4×	3.4k 1.3×	2.9k 1.7×	2.2k 1.4×	2.5k 1.8×	173	9.7k
David Euhus United States	40	3.0k 0.9×	3.1k 1.2×	1.2k 0.7×	1.4k 0.9×	2.4k 1.7×	128	7.5k
Amy C. Degnim United States	49	4.4k 1.4×	2.8k 1.1×	3.3k 1.9×	2.6k 1.6×	888 0.6×	233	8.0k
Ian S. Fentiman United Kingdom	50	4.3k 1.3×	4.2k 1.6×	3.2k 1.9×	1.8k 1.2×	908 0.6×	204	9.6k
David K. Gaffney United States	46	1.6k 0.5×	1.8k 0.7×	844 0.5×	2.0k 1.3×	1.3k 0.9×	318	9.0k

Countries citing papers authored by Seema A. Khan

Since Specialization

Citations

This map shows the geographic impact of Seema A. Khan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Seema A. Khan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Seema A. Khan more than expected).

Fields of papers citing papers by Seema A. Khan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Seema A. Khan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Seema A. Khan. The network helps show where Seema A. Khan may publish in the future.

Co-authorship network of co-authors of Seema A. Khan

This figure shows the co-authorship network connecting the top 25 collaborators of Seema A. Khan. A scholar is included among the top collaborators of Seema A. Khan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Seema A. Khan. Seema A. Khan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hajirahimkhan, Atieh, Elizabeth T. Bartom, Seyyedmohsen Hosseinibarkooie, et al.. (2025). Reprogramming SREBP1 ‐dependent lipogenesis and inflammation in high‐risk breast with licochalcone A: A novel path to cancer prevention. International Journal of Cancer. 158(7). 1927–1940.

Liu, Kun, Radhika Iyer, Yi Li, et al.. (2025). USP22 drives tumor immune evasion and checkpoint blockade resistance through EZH2-mediated epigenetic silencing of MHC-I. Journal of Clinical Investigation. 136(1).

Delaloge, Suzette, et al.. (2024). Ductal carcinoma in situ of the breast: finding the balance between overtreatment and undertreatment. The Lancet. 403(10445). 2734–2746. 10 indexed citations

Khan, Seema A., et al.. (2024). Contralateral Breast Cancer Remains a Complex Biologic Conundrum. JAMA Oncology. 10(9). 1175–1175. 1 indexed citations

Gabel, Kelsey, Mark Ezpeleta, Shuhao Lin, et al.. (2024). Effect of Time-Restricted Eating on Circulating Levels of IGF1 and Its Binding Proteins in Obesity: An Exploratory Analysis of a Randomized Controlled Trial. Nutrients. 16(20). 3476–3476. 3 indexed citations

Butler, Marcus O., Ryan Weight, Rizwan Haq, et al.. (2024). 1139TiP IDE196 (darovasertib) in combination with crizotinib versus investigator’s choice of treatment as first-line therapy in HLA-A2 negative metastatic uveal melanoma. Annals of Oncology. 35. S747–S747. 2 indexed citations

Patel, Anisha B., J. Jack Lee, Diane D. Liu, et al.. (2022). Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer. Cancer Prevention Research. 16(1). 47–55. 4 indexed citations

Korde, Larissa A., Mark R. Somerfield, Lisa A. Carey, et al.. (2021). Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. Journal of Clinical Oncology. 39(13). 1485–1505. 592 indexed citations breakdown →

Fabian, Carol J., Seema A. Khan, Judy E. Garber, et al.. (2020). Randomized Phase IIB Trial of the Lignan Secoisolariciresinol Diglucoside in Premenopausal Women at Increased Risk for Development of Breast Cancer. Cancer Prevention Research. 13(7). 623–634. 19 indexed citations

10.

Visvanathan, Kala, Carol J. Fabian, Elissa Bantug, et al.. (2019). Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update. Journal of Clinical Oncology. 37(33). 3152–3165. 117 indexed citations

11.

Lee, Oukseub, Richard E. Heinz, David Ivancic, et al.. (2018). Breast Hormone Concentrations in Random Fine-Needle Aspirates of Healthy Women Associate with Cytological Atypia and Gene Methylation. Cancer Prevention Research. 11(9). 557–568. 4 indexed citations

12.

Stearns, Vered, Mary Jo Fackler, Zoila A. Lopez‐Bujanda, et al.. (2016). Gene Methylation and Cytological Atypia in Random Fine-Needle Aspirates for Assessment of Breast Cancer Risk. Cancer Prevention Research. 9(8). 673–682. 7 indexed citations

13.

Costa, Fabrício F., Denise Scholtens, Jared M. Bischof, et al.. (2016). Expression of miR-18a and miR-210 in Normal Breast Tissue as Candidate Biomarkers of Breast Cancer Risk. Cancer Prevention Research. 10(1). 89–97. 28 indexed citations

14.

Sacotte, R., John Y. Kim, Mohammed S. Alghoul, et al.. (2016). Assessing long-term complications in patients undergoing immediate postmastectomy breast reconstruction and adjuvant radiation. Practical Radiation Oncology. 7(2). e91–e97. 19 indexed citations

15.

Moran, Meena S., Stuart J. Schnitt, Armando E. Giuliano, et al.. (2014). Society of Surgical Oncology–American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer. Journal of Clinical Oncology. 32(14). 1507–1515. 285 indexed citations

16.

Khan, Seema A., Robert T. Chatterton, Oukseub Lee, et al.. (2012). Soy Isoflavone Supplementation for Breast Cancer Risk Reduction: A Randomized Phase II Trial. Cancer Prevention Research. 5(2). 309–319. 126 indexed citations

17.

Pilewskie, Melissa, Angela J. Fought, Nora Hansen, et al.. (2011). Association between Recency of Last Pregnancy and Biologic Subtype of Breast Cancer. Annals of Surgical Oncology. 19(4). 1167–1173. 36 indexed citations

18.

Fisher, Carla S., V. Suzanne Klimberg, Seema A. Khan, Feng Gao, & Julie A. Margenthaler. (2011). Margin Index Is Not a Reliable Tool for Predicting Residual Disease after Breast-Conserving Surgery for DCIS. Annals of Surgical Oncology. 18(11). 3155–3159. 8 indexed citations

19.

Chen, Feng, Elizabeth L. Wiley, Anjeni Keswani, et al.. (2007). αB-crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in breast cancer. Breast Cancer Research and Treatment. 111(3). 411–417. 54 indexed citations

20.

Badawy, Shawky Z.A., et al.. (1996). The Role of Estradiol, Progesterone, and Transforming Growth Factor on Human Endometrioma Cell Culture. American Journal of Reproductive Immunology. 36(1). 58–63. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact